admin

Kharabi led development of CD19 CAR-T therapy TECARTUS®; brings extensive cell and gene therapy expertise to guide 3T’s bispecific T-cell engager programs into the clinic Knudsen oversees more than 100 immunotherapy studies at PICI; adds deep translational oncology insight to help shape 3T’s scientific and clinical strategy SOUTH SAN FRANCISCO,…

SOUTH SAN FRANCISCO, Calif., March 4, 2025  – 3T Biosciences (“3T”), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the promotion of Marvin Gee, Ph.D., to chief research officer and the appointment of Barbara Sennino, Ph.D., as senior vice president and…

Collaborations with decorated academic investigators at Oxford University, VIB, KU Leuven, and University of California, San Francisco

Ingelheim, Germany and South San Francisco, Calif., USA — 4 January 2023 — Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies. Despite the significant transformation of the cancer treatment landscape…

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., USA, 9 January 2023 – Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class…

Current president and CEO of Intellia Therapeutics and previous global head of Abbvie's R&D brings more than 30 years' experience leading discovery, development, and launch of groundbreaking blockbuster medicines SAN FRANCISCO, Calif., Oct. 25, 2022 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors…

Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations Company secured exclusive license with Stanford University for novel TCR-mimetic discovery platform and development stage MAGE-A3 TCRs Stefan Scherer, M.D., Ph.D., named president and CEO, and Christopher DeRespino, MBA, appointed…